Currently, the best way to assess hepatic fibrosis is liver biopsy; however, it is an invasive procedure that can cause serious side effects. Researchers have been studying less invasive techniques, such as blood tests and imaging strategies like ultrasound, but so far, they have not proven sensitive enough to detect the various stages of fibrosis.
Over the past decade, a number of technological advances have been made in magnetic resonance (MR) imaging of the liver. Researchers led by Jayant Talwalkar of the Mayo Clinic, examined the current state of MR imaging and the studies that looked at its utility in detecting liver fibrosis.
They found that contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopy, and diffusion-weighted magnetic resonance imaging have shown promise for detecting hepatic fibrosis, though they require further refinement.
But the technology that is showing the greatest promise is magnetic resonance elastography, which quantitatively assesses tissue stiffness. Recent studies have shown that MR elastography has high sensitivity and specificity in detecting fibrosis stages. “As with other techniques, efforts to standardize the equipment and techniques used for MR elastography should be pursued to maximize diagnostic accuracy and facilitate comparison of results in different settings,” the authors suggest. “Reproducibility appears good from initial studies but requires additional study for verification.”.
The authors emphasize that the design and conduct of high-quality diagnostic accuracy studies is essential for ongoing validation of these emerging non-invasive techniques for determining hepatic fibrosis. Most relevant studies to date have included small numbers of patients and lacked independent assessment, issues that should be addressed in future studies.
Once MRI techniques have become suitably advanced, patients will likely prefer them to liver biopsy. “While the number of patients screened for hepatic fibrosis may increase using MR imaging, proof will be required that early detection and intervention can reduce morbidity and resource utilization associated with the clinical sequelae of advanced disease,” the authors point out.
“The development of a reliable and valid non-invasive method to assess hepatic fibrosis could result in comparable or, perhaps, improved accuracy in terms of staging,” they conclude. “The emergence of MR imaging techniques (singly or in combination with other methods) could result in the performance of true functional hepatic imaging.”
Source: Wiley-Blackwell
Related stories:
New findings: The anti-fibrotic mechanism of plant extract Cpd 861
A team led by Dr. Xue-Hai Tan from the Beijing Genomics Institute has determined that the antifibrotic function of Chinese herbal extract Cpd 861 is mediated by both downregulating the synthesis of collagens and upregulating the degradation of collagens. This effect is evidently different from that of Western antifibrogenic drugs and could allow for the development of effective antifibrogenic drugs from Chinese medicinal herbs.
Serum fibrosis markers correlate with liver fibrosis stage in patients with advanced chronic hep C
A prospective study of patients with advanced chronic hepatitis C (CHC) revealed that a 3-variable model of serum fibrosis markers, including serum HA, TIMP-1 and platelet count, could identify cirrhosis with better accuracy than other published models. These findings are in the March issue of
Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).
Attention: Extra-hepatic manifestation of hepatitis C virus infection
In 1994, the team of Tchernev and Petrova from Alexandrovska Hospital in Sofia examined a female patient with liver cirrhosis caused by chronic Hepatitis C virus (HCV). They were intrigued by the patient's many extra-hepatic manifestations -- vascular lesions on the lower limbs, acute pain in the joints, intense tingling of the fingers, and extreme labor-impairing fatigue.
Researchers show that fibrosis can be stopped, cured and reversed
University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed. Their discovery, to be published in
PLoS Online on December 26, opens the door to treating and curing conditions that lead to excessive tissue scarring such as viral hepatitis, fatty liver disease, cirrhosis, pulmonary fibrosis, scleroderma and burns.
MRI predicts liver fibrosis, study says
Moderate to severe chronic liver disease can be predicted with the use of diffusion-weighted MRI (DWI), according to a recent study conducted by researchers at New York University Medical Center in New York, NY.
First pharmaceutical drug to improve survival amongst patients with advanced hepatocarcinoma
International research involving the University Hospital of the University of Navarra, together with other hospitals in Spain, has shown that Sorafenib, an orally administered pharmaceutical medicine, results in patients with primary hepatocarcinomas (liver tumours) to live 40% more on average compared to those not taking the drug. The study, led by the Barcelona Hospital Clinic, will be shortly published in the
New England Journal of Medicine.
Researchers determine risk factors for infection after liver transplantation
Nearly 9 percent of patients who recently underwent liver transplantation suffered a subsequent surgical site infection (SSI). Risk factors included having had biliary-enteric anastomosis (choledocho-jejunal or hepatic-jejunal reconstruction), previous liver or kidney transplant, and more than four red blood cell units transfused. These findings are published in the June issue of Liver Transplantation, a journal by John Wiley & Sons.
Ashwell receptor reduces mortality during sepsis
In research that solves the longest-standing mystery in glycobiology – a field that studies complex sugar chains called glycans – researchers at the University of California, San Diego School of Medicine have discovered that a molecule in the liver of all animals, called the Ashwell receptor, is critical in helping the body fight off the abnormal and lethal blood clotting caused by bacterial infection. Until now, it was suspected that this receptor might serve to remove abnormal proteins from circulation, but it wasn’t understood which proteins were affected or what biological purpose this receptor served.